胰腺癌患者治疗进展：症状改善与生存时间延长。圣安东尼奥药物研发团队。
Advances in the treatment of patients with pancreatic cancer: improvement in symptoms and survival time. The San Antonio Drug Development Team.
作者信息
Von Hoff D D, Goodwin A L, Garcia L
机构信息
Institute for Drug Development, Cancer Therapy & Research Center, San Antonio, Texas 78245, USA.
出版信息
Br J Cancer. 1998;78 Suppl 3(Suppl 3):9-13. doi: 10.1038/bjc.1998.748.
Pancreatic cancer is a major cause of death from cancer in both men and women in the USA and Europe. The disease causes pain and has a significant impact on the performance status of the patient. In a randomized trial vs 5-fluorouracil, the novel nucleoside analogue gemcitabine (GEMZAR) has been shown to provide clinical benefit for patients (decreased pain and improved performance status) as well as to improve the time to tumour progression and survival for patients with the disease. There are also other new agents that are presented in this discussion, such as the multi-targeted antifolate MTA, capecitabine and the ONYX-015 adenovirus, which replicates in, and kills, only p53-abnormal cells, which have the potential to have an impact on this terrible disease.
在美国和欧洲，胰腺癌是导致男性和女性癌症死亡的主要原因。这种疾病会引发疼痛，并对患者的身体状况产生重大影响。在一项与5-氟尿嘧啶对比的随机试验中，新型核苷类似物吉西他滨（健择）已被证明能为患者带来临床益处（减轻疼痛并改善身体状况），还能延长该疾病患者的肿瘤进展时间并提高生存率。本次讨论中还提到了其他一些新型药物，比如多靶点抗叶酸药物MTA、卡培他滨以及ONYX - 015腺病毒，后者仅在p53异常的细胞中复制并将其杀死，这些药物都有可能对这种可怕的疾病产生影响。
Zotero 插件